APDN vs. XBP, BTCM, FPAY, ISDR, SCOR, SJ, VIVK, SWVL, LUNA, and HTCR
Should you be buying Applied DNA Sciences stock or one of its competitors? The main competitors of Applied DNA Sciences include XBP Europe (XBP), BIT Mining (BTCM), FlexShopper (FPAY), Issuer Direct (ISDR), comScore (SCOR), Scienjoy (SJ), Vivakor (VIVK), Swvl (SWVL), Luna Innovations (LUNA), and HeartCore Enterprises (HTCR). These companies are all part of the "business services" industry.
Applied DNA Sciences vs.
XBP Europe (NASDAQ:XBP) and Applied DNA Sciences (NASDAQ:APDN) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
Applied DNA Sciences received 293 more outperform votes than XBP Europe when rated by MarketBeat users.
In the previous week, XBP Europe had 1 more articles in the media than Applied DNA Sciences. MarketBeat recorded 3 mentions for XBP Europe and 2 mentions for Applied DNA Sciences. Applied DNA Sciences' average media sentiment score of 0.71 beat XBP Europe's score of 0.36 indicating that Applied DNA Sciences is being referred to more favorably in the news media.
Applied DNA Sciences has lower revenue, but higher earnings than XBP Europe.
Applied DNA Sciences has a consensus price target of $1.50, suggesting a potential upside of 855.41%. Given Applied DNA Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Applied DNA Sciences is more favorable than XBP Europe.
XBP Europe has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, Applied DNA Sciences has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.
XBP Europe has a net margin of -9.50% compared to Applied DNA Sciences' net margin of -228.12%. XBP Europe's return on equity of 0.00% beat Applied DNA Sciences' return on equity.
15.7% of XBP Europe shares are owned by institutional investors. Comparatively, 22.2% of Applied DNA Sciences shares are owned by institutional investors. 82.5% of XBP Europe shares are owned by company insiders. Comparatively, 0.2% of Applied DNA Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Applied DNA Sciences beats XBP Europe on 9 of the 15 factors compared between the two stocks.
Get Applied DNA Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied DNA Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:APDN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free APDN Stock Alerts